CD44 and neoplasm: In summary, we found that IR with the PTV95 program (a higher radiotherapy dose) resulted in increased radioresistance than IR with the Non‐PTV95 program (a lower radiotherapy dose), and the tumor microenvironment (CD44 level) may enhance radioresistance in IR with the Non‐PTV95 program.